VRCAVerrica Pharmaceuticals Inc.

$56M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+2823.5% YoY

Gross Profit

-$19M-934.6% margin

Operating Income

-$23M-1163.8% margin

Net Income

-$25M-1238.1% margin

EPS (Diluted)

$-5.31

QoQ Revenue Growth

-31.8%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$82M

Total Liabilities

$62M

Stockholders' Equity

$20M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$68,000	+2823.5%
Gross Profit	-$19M	-$3M	-514.8%
Operating Income	-$23M	-$6M	-272.5%
Net Income	-$25M	-$6M	-314.9%

Revenue Segments

Product

$2M85%

Collaboration

$341,00015%

VRCA Q4 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena